Assignee
HUMANIGEN INC
US·7 granted patents·14 pending applications·8 citations·filing 2015–2022
Top patents by PatentIndex Score
21 records- 0186US10870703B2Methods of treating immunotherapy-related toxicity using a GM-CSF antagonistHUMANIGEN INC·Filed 2018·Granted Dec 22, 2020·3 cites·82 claims
- 0283US10927168B2Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumabHUMANIGEN INC·Filed 2019·Granted Feb 23, 2021·2 cites·37 claims
- 0383US10899831B2Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicityHUMANIGEN INC·Filed 2018·Granted Jan 26, 2021·2 cites·14 claims
- 0477US11673962B2Method of increasing the efficacy of CAR-T immunotherapy using lenzilumabHUMANIGEN INC·Filed 2018·Granted Jun 13, 2023·1 cites·16 claims
- 0562US12139544B2EphA3 directed CAR-T cells for treatment of tumorsHUMANIGEN INC·Filed 2020·Granted Nov 12, 2024·0 cites·21 claims
- 0662US2021130488A1Methods of treating immunotherapy-related toxicity using a gm-csf antagonistHUMANIGEN INC·Filed 2020·Application pending·0 cites
- 0758US2021230262A1Methods of treating immunotherapy-related toxicity using a gm-csf antagonistHUMANIGEN INC·Filed 2021·Application pending·0 cites
- 0858US2022025034A1Methods of treating immunotherapy-related toxicity using a gm-csf antagonistHUMANIGEN INC·Filed 2021·Application pending·0 cites
- 0958US2021269518A1Methods of treating immunotherapy-related toxicity using a gm-csf antagonistHUMANIGEN INC·Filed 2021·Application pending·0 cites
- 1058US2021284714A1Materials and methods for treating cancerHUMANIGEN INC·Filed 2021·Application pending·0 cites
- 1155US11130805B2Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonistHUMANIGEN INC·Filed 2019·Granted Sep 28, 2021·0 cites·32 claims
- 1255US2024317846A1Methods for treating coronavirus infection and resulting inflammation-induced lung injuryHUMANIGEN INC·Filed 2022·Application pending·0 cites
- 1354US2022040229A1Materials and methods for treating cancerHUMANIGEN INC·Filed 2019·Application pending·0 cites
- 1454US2024158467A1Materials and methods for treating cancerHUMANIGEN INC·Filed 2022·Application pending·0 cites
- 1551US2023109208A1Methods for treating coronavirus infection and resulting inflammation-induced lung injuryHUMANIGEN INC·Filed 2021·Application pending·0 cites
- 1651US2022363746A1Methods for treating coronavirus infection and resulting inflammation-induced lung injuryHUMANIGEN INC·Filed 2021·Application pending·0 cites
- 1751US2021322547A1Methods of treating immunotherapy-related toxicity using a gm-csf antagonistHUMANIGEN INC·Filed 2021·Application pending·0 cites
- 1851US2021309733A1Methods for treating coronavirus infection and resulting inflammation-induced lung injuryHUMANIGEN INC·Filed 2021·Application pending·0 cites
- 1950US10919983B2Immunoglobulin variable region cassette exchangeHUMANIGEN INC·Filed 2015·Granted Feb 16, 2021·0 cites·19 claims
- 2049US2021290677A1Methods of treating immunotherapy-related toxicity using a gm-csf antagonistHUMANIGEN INC·Filed 2019·Application pending·0 cites
- 2142US2019270821A1Epha3 antibodies for the treatment of pulmonary fibrosisHUMANIGEN INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when HUMANIGEN INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →